| 14.54 Real-Time Quote |  +0.14 / +0.97%Today’s Change | 9.13 Today|||52-Week Range 16.29 | +46.28% Year-to-Date |
| Biogen's Hemophilia BLA Accepted - Analyst Blog 10:10am / Zacks.com | Amgen to Set Up JV in China - Analyst Blog May 14 / Zacks.com |
| SGEN's Adcetris under FDA Review - Analyst Blog May 16 / Zacks.com | Disappointing 1Q Earnings for IART - Analyst Blog May 10 / Zacks.com |
| Pediatric Approval for MDCO/BMY's Recothrom - Analyst Blog May 15 / Zacks.com | Wider-than-Expected Loss at Dynavax - Analyst Blog May 07 / Zacks.com |
| Previous close | 14.40 |
| Today’s open | 14.43 |
| Day’s range | 14.31 - 14.75 |
| Volume | 30,771 |
| Average volume (3 months) | 94,801 |
| Market cap | $201.5M |
| Dividend yield | -- |
| Earnings growth (last year) | +32.26% |
| Earnings growth (this year) | +26.42% |
| Earnings growth (next 5 years) | +30.00% |
| Revenue growth (last year) | +10.16% |
| P/E ratio | 16.4 |
| Price/Sales | 1.85 |
| Price/Book | 1.83 |
| Today’s change | Today’s % change | |
|---|---|---|
| ATRCAtriCure Inc | +0.10 | +1.10% |
| UTMDUtah Medical Product... | +0.52 | +1.05% |
| ROCMRochester Medical Co... | +0.01 | +0.07% |
| CYTXCytori Therapeutics ... | -0.07 | -2.66% |
| Next reporting date | July 23, 2013 |
| EPS forecast (this quarter) | $0.25 |
| Annual revenue (last year) | $71.4M |
| Annual profit (last year) | $11.8M |
| Net profit margin | 16.48% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Charles H. Sherwood, PhD |
Chief Operating Officer Francesco J. Luppino |
Corporate headquarters Bedford, Massachusetts |
.
